DDInter717 DDInter1397
Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Fenfluramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Tolterodine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Paroxetine
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Paroxetine
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolmetin
Tolmetin {u} (Compound) downregulates {v} (Gene) IARS2
IARS2 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Fenfluramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxone
Naloxone {u} (Compound) downregulates {v} (Gene) NT5DC2
NT5DC2 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Fenfluramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Donepezil {u} (Compound) upregulates {v} (Gene) NFIL3
NFIL3 {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Argatroban
Argatroban {u} (Compound) causes {v} (Side Effect) Haemorrhage
Haemorrhage {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} (Compound) causes {v} (Side Effect) Erythema multiforme
Erythema multiforme {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Fenfluramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxone
Naloxone {u} (Compound) causes {v} (Side Effect) Ventricular tachycardia
Ventricular tachycardia {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Indomethacin
Indomethacin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Paroxetine
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acarbose
Acarbose {u} (Compound) downregulates {v} (Gene) TRIB3
TRIB3 {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterodine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Paroxetine (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Paroxetine (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tolmetin (Compound) downregulates IARS2 (Gene) and IARS2 (Gene) is downregulated by Paroxetine (Compound)
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Naloxone and Naloxone (Compound) downregulates NT5DC2 (Gene) and NT5DC2 (Gene) is downregulated by Paroxetine (Compound)
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil (Compound) upregulates NFIL3 (Gene) and NFIL3 (Gene) is upregulated by Paroxetine (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Argatroban and Argatroban (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Paroxetine (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Paroxetine (Compound)
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Naloxone and Naloxone (Compound) causes Ventricular tachycardia (Side Effect) and Ventricular tachycardia (Side Effect) is caused by Paroxetine (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Paroxetine (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose (Compound) downregulates TRIB3 (Gene) and TRIB3 (Gene) is upregulated by Paroxetine (Compound)